Leprosy	B:C0343461
reactions	I:C0343461
:	O

The	O
predictive	O
value	O
of	O
Mycobacterium	B:C0026922
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	B:C0220825
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	B:C0599755
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	B:C0023343
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	B:C0013216
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	B:C0006137
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	B:C0343461
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	B:C0343461
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	B:C0343461
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	B:C0343467
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	B:C0343467
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	B:C0161479
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	B:C0231172
and	O
deformities	O
.	O

The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
)	O
Leprosy	O
reactions	I:C0343461
,	O
reversal	O
reactions	I:C0343461
/	O
RR	O
and	O
erythema	O
nodosum	I:C0343467
leprosum	I:C0343467
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	I:C0161479
,	O
handicaps	O
and	O
deformities	B:C0302142
.	O

The	O
study	O
of	O
Mycobacterium	B:C0026922
leprae	I:C0026922
-	O
specific	O
serologic	O
responses	O
at	O
diagnosis	O
in	O
the	O
cohort	O
of	O
patients	O
enrolled	O
at	O
the	O
Clinical	O
Trial	I:C0008976
for	O
Uniform	O
Multidrug	O
Therapy	I:C0013216
Regimen	O
for	O
Leprosy	O
Patients	O
in	O
Brazil	O
/	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
is	O
suitable	O
to	O
evaluate	O
its	O
prognostic	O
value	O
for	O
the	O
development	O
of	O
reactions	O
.	O

The	O
study	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serologic	O
responses	O
at	O
diagnosis	B:C0011900
in	O
the	O
cohort	O
of	O
patients	O
enrolled	O
at	O
the	O
Clinical	O
Trial	I:C0008976
for	O
Uniform	O
Multidrug	O
Therapy	I:C0013216
Regimen	O
for	O
Leprosy	O
Patients	O
in	O
Brazil	O
/	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
is	O
suitable	O
to	O
evaluate	O
its	O
prognostic	O
value	O
for	O
the	O
development	O
of	O
reactions	O
.	O

The	O
study	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serologic	O
responses	O
at	O
diagnosis	O
in	O
the	O
cohort	B:C0599755
of	O
patients	O
enrolled	O
at	O
the	O
Clinical	O
Trial	I:C0008976
for	O
Uniform	O
Multidrug	O
Therapy	I:C0013216
Regimen	O
for	O
Leprosy	O
Patients	O
in	O
Brazil	O
/	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
is	O
suitable	O
to	O
evaluate	O
its	O
prognostic	O
value	O
for	O
the	O
development	O
of	O
reactions	O
.	O

The	O
study	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serologic	O
responses	O
at	O
diagnosis	O
in	O
the	O
cohort	O
of	O
patients	O
enrolled	O
at	O
the	O
Clinical	B:C0008976
Trial	I:C0008976
for	O
Uniform	O
Multidrug	O
Therapy	I:C0013216
Regimen	O
for	O
Leprosy	O
Patients	O
in	O
Brazil	O
/	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
is	O
suitable	O
to	O
evaluate	O
its	O
prognostic	O
value	O
for	O
the	O
development	O
of	O
reactions	O
.	O

The	O
study	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serologic	O
responses	O
at	O
diagnosis	O
in	O
the	O
cohort	O
of	O
patients	O
enrolled	O
at	O
the	O
Clinical	O
Trial	I:C0008976
for	O
Uniform	O
Multidrug	B:C0013216
Therapy	I:C0013216
Regimen	O
for	O
Leprosy	O
Patients	O
in	O
Brazil	O
/	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
is	O
suitable	O
to	O
evaluate	O
its	O
prognostic	O
value	O
for	O
the	O
development	O
of	O
reactions	O
.	O

The	O
study	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serologic	O
responses	O
at	O
diagnosis	O
in	O
the	O
cohort	O
of	O
patients	O
enrolled	O
at	O
the	O
Clinical	O
Trial	I:C0008976
for	O
Uniform	O
Multidrug	O
Therapy	I:C0013216
Regimen	O
for	O
Leprosy	B:C0023343
Patients	O
in	O
Brazil	O
/	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
is	O
suitable	O
to	O
evaluate	O
its	O
prognostic	O
value	O
for	O
the	O
development	O
of	O
reactions	O
.	O

The	O
study	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serologic	O
responses	O
at	O
diagnosis	O
in	O
the	O
cohort	O
of	O
patients	O
enrolled	O
at	O
the	O
Clinical	O
Trial	I:C0008976
for	O
Uniform	O
Multidrug	O
Therapy	I:C0013216
Regimen	O
for	O
Leprosy	O
Patients	O
in	O
Brazil	B:C0006137
/	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
is	O
suitable	O
to	O
evaluate	O
its	O
prognostic	O
value	O
for	O
the	O
development	O
of	O
reactions	O
.	O

The	O
study	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serologic	O
responses	O
at	O
diagnosis	O
in	O
the	O
cohort	O
of	O
patients	O
enrolled	O
at	O
the	O
Clinical	O
Trial	I:C0008976
for	O
Uniform	O
Multidrug	O
Therapy	I:C0013216
Regimen	O
for	O
Leprosy	O
Patients	O
in	O
Brazil	O
/	O
U	B:C0013216
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
is	O
suitable	O
to	O
evaluate	O
its	O
prognostic	O
value	O
for	O
the	O
development	O
of	O
reactions	O
.	O

The	O
study	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serologic	O
responses	O
at	O
diagnosis	O
in	O
the	O
cohort	O
of	O
patients	O
enrolled	O
at	O
the	O
Clinical	O
Trial	I:C0008976
for	O
Uniform	O
Multidrug	O
Therapy	I:C0013216
Regimen	O
for	O
Leprosy	O
Patients	O
in	O
Brazil	O
/	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	B:C0006137
-	I:C0006137
BR	I:C0006137
is	O
suitable	O
to	O
evaluate	O
its	O
prognostic	O
value	O
for	O
the	O
development	O
of	O
reactions	O
.	O

The	O
study	O
of	O
Mycobacterium	O
leprae	I:C0026922
-	O
specific	O
serologic	O
responses	O
at	O
diagnosis	O
in	O
the	O
cohort	O
of	O
patients	O
enrolled	O
at	O
the	O
Clinical	O
Trial	I:C0008976
for	O
Uniform	O
Multidrug	O
Therapy	I:C0013216
Regimen	O
for	O
Leprosy	O
Patients	O
in	O
Brazil	O
/	O
U	O
-	I:C0013216
MDT	I:C0013216
/	O
CT	O
-	I:C0006137
BR	I:C0006137
is	O
suitable	O
to	O
evaluate	B:C0220825
its	O
prognostic	O
value	O
for	O
the	O
development	O
of	O
reactions	O
.	O

IgM	B:C0020861
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	B:C0020852
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	B:C0003261
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	B:C0070575
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	B:C0003320
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	B:C0003320
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	B:C0220825
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	B:C0014441
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	B:C0442740
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	B:C0023343
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	B:C0011900
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	B:C0030695
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	B:C0343461
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	B:C0027361
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	B:C0027361
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	B:C0027361
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	O
-	I:C1522577
up	I:C1522577
time	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	I:C0003261
to	O
PGL	O
-	I:C0070575
I	I:C0070575
,	O
LID	O
-1	I:C0003320
,	O
ND	O
-	I:C0003320
O	I:C0003320
-	I:C0003320
LID	I:C0003320
were	O
evaluated	O
by	O
ELISA	O
in	O
452	O
reaction	O
-	I:C0442740
free	I:C0442740
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	I:C0343461
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e.	O
2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
time	O
.	O

Among	O
these	O
patients	O
,	O
36	O
%	O
(	O
160/452	O
)	O
developed	O
reactions	O
during	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
:	O
26	O
%	O
(	O
119/452	O
)	O
RR	O
and	O
10	O
%	O
(	O
41/452	O
)	O
had	O
ENL	O
.	O

Among	O
these	O
patients	O
,	O
36	O
%	O
(	O
160/452	O
)	O
developed	O
reactions	O
during	O
follow	O
-	I:C1522577
up	I:C1522577
:	O
26	O
%	O
(	O
119/452	O
)	O
RR	B:C0343461
and	O
10	O
%	O
(	O
41/452	O
)	O
had	O
ENL	O
.	O

Among	O
these	O
patients	O
,	O
36	O
%	O
(	O
160/452	O
)	O
developed	O
reactions	O
during	O
follow	O
-	I:C1522577
up	I:C1522577
:	O
26	O
%	O
(	O
119/452	O
)	O
RR	O
and	O
10	O
%	O
(	O
41/452	O
)	O
had	O
ENL	B:C0343467
.	O

At	O
baseline	O
higher	O
anti-PGL	B:C0243095
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
seropositivity	O
rates	O
were	O
seen	O
in	O
patients	O
who	O
developed	O
ENL	O
and	O
RR	O
compared	O
to	O
reaction	O
-	I:C0442740
free	I:C0442740
patients	O
(	O
p<0.0001	O
)	O
.	O

At	O
baseline	O
higher	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	B:C0243095
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
seropositivity	O
rates	O
were	O
seen	O
in	O
patients	O
who	O
developed	O
ENL	O
and	O
RR	O
compared	O
to	O
reaction	O
-	I:C0442740
free	I:C0442740
patients	O
(	O
p<0.0001	O
)	O
.	O

At	O
baseline	O
higher	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	B:C0243095
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
seropositivity	O
rates	O
were	O
seen	O
in	O
patients	O
who	O
developed	O
ENL	O
and	O
RR	O
compared	O
to	O
reaction	O
-	I:C0442740
free	I:C0442740
patients	O
(	O
p<0.0001	O
)	O
.	O

At	O
baseline	O
higher	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
seropositivity	O
rates	O
were	O
seen	O
in	O
patients	O
who	O
developed	O
ENL	B:C0343467
and	O
RR	O
compared	O
to	O
reaction	O
-	I:C0442740
free	I:C0442740
patients	O
(	O
p<0.0001	O
)	O
.	O

At	O
baseline	O
higher	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
seropositivity	O
rates	O
were	O
seen	O
in	O
patients	O
who	O
developed	O
ENL	O
and	O
RR	B:C0343461
compared	O
to	O
reaction	O
-	I:C0442740
free	I:C0442740
patients	O
(	O
p<0.0001	O
)	O
.	O

At	O
baseline	O
higher	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
seropositivity	O
rates	O
were	O
seen	O
in	O
patients	O
who	O
developed	O
ENL	O
and	O
RR	O
compared	O
to	O
reaction	B:C0442740
-	I:C0442740
free	I:C0442740
patients	O
(	O
p<0.0001	O
)	O
.	O

Seroreactivity	O
in	O
reactional	O
and	O
reaction	B:C0442740
-	I:C0442740
free	I:C0442740
patients	O
was	O
stratified	O
by	O
bacilloscopic	O
index	O
/	O
BI	O
categories	O
.	O

Among	O
BI	O
negative	B:C0205160
patients	O
,	O
higher	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
levels	O
were	O
seen	O
in	O
RR	O
compared	O
to	O
reaction	O
-	I:C0442740
free	I:C0442740
patients	O
(	O
p	O
=	O
0.014	O
)	O
.	O

Among	O
BI	O
negative	O
patients	O
,	O
higher	O
anti-PGL	B:C0243095
-	I:C0243095
I	I:C0243095
levels	O
were	O
seen	O
in	O
RR	O
compared	O
to	O
reaction	O
-	I:C0442740
free	I:C0442740
patients	O
(	O
p	O
=	O
0.014	O
)	O
.	O

Among	O
BI	O
negative	O
patients	O
,	O
higher	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
levels	O
were	O
seen	O
in	O
RR	B:C0343461
compared	O
to	O
reaction	O
-	I:C0442740
free	I:C0442740
patients	O
(	O
p	O
=	O
0.014	O
)	O
.	O

Among	O
BI	O
negative	O
patients	O
,	O
higher	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
levels	O
were	O
seen	O
in	O
RR	O
compared	O
to	O
reaction	B:C0442740
-	I:C0442740
free	I:C0442740
patients	O
(	O
p	O
=	O
0.014	O
)	O
.	O

In	O
patients	O
with	O
0	O
<	O
BI	O
<	O
3	O
,	O
(	O
36	O
RR	B:C0343461
,	O
36	O
reaction	O
-	I:C0442740
free	I:C0442740
)	O
,	O
higher	O
antibody	O
levels	O
to	O
PGL	O
-	I:C0070575
I	I:C0070575
(	O
p	O
=	O
0.014	O
)	O
and	O
to	O
LID	O
-	I:C0003320
1	I:C0003320
(	O
p	O
=	O
0.035	O
)	O
were	O
seen	O
in	O
RR	O
while	O
difference	O
in	O
anti-ND	O
-	I:C0243095
O	I:C0243095
-	I:C0243095
LID	I:C0243095
positivity	O
was	O
borderline	O
(	O
p	O
=	O
0.052	O
)	O
.	O

In	O
patients	O
with	O
0	O
<	O
BI	O
<	O
3	O
,	O
(	O
36	O
RR	O
,	O
36	O
reaction	B:C0442740
-	I:C0442740
free	I:C0442740
)	O
,	O
higher	O
antibody	O
levels	O
to	O
PGL	O
-	I:C0070575
I	I:C0070575
(	O
p	O
=	O
0.014	O
)	O
and	O
to	O
LID	O
-	I:C0003320
1	I:C0003320
(	O
p	O
=	O
0.035	O
)	O
were	O
seen	O
in	O
RR	O
while	O
difference	O
in	O
anti-ND	O
-	I:C0243095
O	I:C0243095
-	I:C0243095
LID	I:C0243095
positivity	O
was	O
borderline	O
(	O
p	O
=	O
0.052	O
)	O
.	O

In	O
patients	O
with	O
0	O
<	O
BI	O
<	O
3	O
,	O
(	O
36	O
RR	O
,	O
36	O
reaction	O
-	I:C0442740
free	I:C0442740
)	O
,	O
higher	O
antibody	B:C0003241
levels	O
to	O
PGL	O
-	I:C0070575
I	I:C0070575
(	O
p	O
=	O
0.014	O
)	O
and	O
to	O
LID	O
-	I:C0003320
1	I:C0003320
(	O
p	O
=	O
0.035	O
)	O
were	O
seen	O
in	O
RR	O
while	O
difference	O
in	O
anti-ND	O
-	I:C0243095
O	I:C0243095
-	I:C0243095
LID	I:C0243095
positivity	O
was	O
borderline	O
(	O
p	O
=	O
0.052	O
)	O
.	O

In	O
patients	O
with	O
0	O
<	O
BI	O
<	O
3	O
,	O
(	O
36	O
RR	O
,	O
36	O
reaction	O
-	I:C0442740
free	I:C0442740
)	O
,	O
higher	O
antibody	O
levels	O
to	O
PGL	B:C0070575
-	I:C0070575
I	I:C0070575
(	O
p	O
=	O
0.014	O
)	O
and	O
to	O
LID	O
-	I:C0003320
1	I:C0003320
(	O
p	O
=	O
0.035	O
)	O
were	O
seen	O
in	O
RR	O
while	O
difference	O
in	O
anti-ND	O
-	I:C0243095
O	I:C0243095
-	I:C0243095
LID	I:C0243095
positivity	O
was	O
borderline	O
(	O
p	O
=	O
0.052	O
)	O
.	O

In	O
patients	O
with	O
0	O
<	O
BI	O
<	O
3	O
,	O
(	O
36	O
RR	O
,	O
36	O
reaction	O
-	I:C0442740
free	I:C0442740
)	O
,	O
higher	O
antibody	O
levels	O
to	O
PGL	O
-	I:C0070575
I	I:C0070575
(	O
p	O
=	O
0.014	O
)	O
and	O
to	O
LID	B:C0003320
-	I:C0003320
1	I:C0003320
(	O
p	O
=	O
0.035	O
)	O
were	O
seen	O
in	O
RR	O
while	O
difference	O
in	O
anti-ND	O
-	I:C0243095
O	I:C0243095
-	I:C0243095
LID	I:C0243095
positivity	O
was	O
borderline	O
(	O
p	O
=	O
0.052	O
)	O
.	O

In	O
patients	O
with	O
0	O
<	O
BI	O
<	O
3	O
,	O
(	O
36	O
RR	O
,	O
36	O
reaction	O
-	I:C0442740
free	I:C0442740
)	O
,	O
higher	O
antibody	O
levels	O
to	O
PGL	O
-	I:C0070575
I	I:C0070575
(	O
p	O
=	O
0.014	O
)	O
and	O
to	O
LID	O
-	I:C0003320
1	I:C0003320
(	O
p	O
=	O
0.035	O
)	O
were	O
seen	O
in	O
RR	B:C0343461
while	O
difference	O
in	O
anti-ND	O
-	I:C0243095
O	I:C0243095
-	I:C0243095
LID	I:C0243095
positivity	O
was	O
borderline	O
(	O
p	O
=	O
0.052	O
)	O
.	O

In	O
patients	O
with	O
0	O
<	O
BI	O
<	O
3	O
,	O
(	O
36	O
RR	O
,	O
36	O
reaction	O
-	I:C0442740
free	I:C0442740
)	O
,	O
higher	O
antibody	O
levels	O
to	O
PGL	O
-	I:C0070575
I	I:C0070575
(	O
p	O
=	O
0.014	O
)	O
and	O
to	O
LID	O
-	I:C0003320
1	I:C0003320
(	O
p	O
=	O
0.035	O
)	O
were	O
seen	O
in	O
RR	O
while	O
difference	O
in	O
anti-ND	B:C0243095
-	I:C0243095
O	I:C0243095
-	I:C0243095
LID	I:C0243095
positivity	O
was	O
borderline	O
(	O
p	O
=	O
0.052	O
)	O
.	O

In	O
patients	O
with	O
0	O
<	O
BI	O
<	O
3	O
,	O
(	O
36	O
RR	O
,	O
36	O
reaction	O
-	I:C0442740
free	I:C0442740
)	O
,	O
higher	O
antibody	O
levels	O
to	O
PGL	O
-	I:C0070575
I	I:C0070575
(	O
p	O
=	O
0.014	O
)	O
and	O
to	O
LID	O
-	I:C0003320
1	I:C0003320
(	O
p	O
=	O
0.035	O
)	O
were	O
seen	O
in	O
RR	O
while	O
difference	O
in	O
anti-ND	O
-	I:C0243095
O	I:C0243095
-	I:C0243095
LID	I:C0243095
positivity	B:C1446409
was	O
borderline	O
(	O
p	O
=	O
0.052	O
)	O
.	O

Patients	O
with	O
BI	O
≥3	O
that	O
developed	O
ENL	B:C0343467
had	O
higher	O
levels	O
of	O
anti-LID	O
-	I:C0243095
1	I:C0243095
antibodies	O
(	O
p	O
=	O
0.028	O
)	O
compared	O
to	O
reaction	O
-	I:C0442740
free	I:C0442740
patients	O
.	O

Patients	O
with	O
BI	O
≥3	O
that	O
developed	O
ENL	O
had	O
higher	O
levels	O
of	O
anti-LID	B:C0243095
-	I:C0243095
1	I:C0243095
antibodies	O
(	O
p	O
=	O
0.028	O
)	O
compared	O
to	O
reaction	O
-	I:C0442740
free	I:C0442740
patients	O
.	O

Patients	O
with	O
BI	O
≥3	O
that	O
developed	O
ENL	O
had	O
higher	O
levels	O
of	O
anti-LID	O
-	I:C0243095
1	I:C0243095
antibodies	B:C0003241
(	O
p	O
=	O
0.028	O
)	O
compared	O
to	O
reaction	O
-	I:C0442740
free	I:C0442740
patients	O
.	O

Patients	O
with	O
BI	O
≥3	O
that	O
developed	O
ENL	O
had	O
higher	O
levels	O
of	O
anti-LID	O
-	I:C0243095
1	I:C0243095
antibodies	O
(	O
p	O
=	O
0.028	O
)	O
compared	O
to	O
reaction	B:C0442740
-	I:C0442740
free	I:C0442740
patients	O
.	O

Anti-PGL	B:C0243095
-	I:C0243095
I	I:C0243095
serology	O
had	O
a	O
limited	O
predictive	O
value	O
for	O
RR	O
according	O
to	O
receiver	O
operating	O
curve	O
/	O
ROC	O
analyses	O
(	O
area	O
-	O
under	O
-	O
the	O
-	O
curve	O
/	O
AUC	O
=	O
0.7	O
)	O
.	O

Anti-PGL	O
-	I:C0243095
I	I:C0243095
serology	B:C0036743
had	O
a	O
limited	O
predictive	O
value	O
for	O
RR	O
according	O
to	O
receiver	O
operating	O
curve	O
/	O
ROC	O
analyses	O
(	O
area	O
-	O
under	O
-	O
the	O
-	O
curve	O
/	O
AUC	O
=	O
0.7	O
)	O
.	O

Anti-PGL	O
-	I:C0243095
I	I:C0243095
serology	O
had	O
a	O
limited	O
predictive	O
value	O
for	O
RR	B:C0343461
according	O
to	O
receiver	O
operating	O
curve	O
/	O
ROC	O
analyses	O
(	O
area	O
-	O
under	O
-	O
the	O
-	O
curve	O
/	O
AUC	O
=	O
0.7	O
)	O
.	O

Anti	B:C0243095
LID	I:C0243095
-	I:C0243095
1	I:C0243095
serology	O
at	O
baseline	O
showed	O
the	O
best	O
performance	O
to	O
predict	O
ENL	O
(	O
AUC	O
0.85	O
)	O
.	O

Anti	O
LID	I:C0243095
-	I:C0243095
1	I:C0243095
serology	B:C0036743
at	O
baseline	O
showed	O
the	O
best	O
performance	O
to	O
predict	O
ENL	O
(	O
AUC	O
0.85	O
)	O
.	O

Anti	O
LID	I:C0243095
-	I:C0243095
1	I:C0243095
serology	O
at	O
baseline	O
showed	O
the	O
best	O
performance	O
to	O
predict	O
ENL	B:C0343467
(	O
AUC	O
0.85	O
)	O
.	O

Overall	O
,	O
detection	B:C0442726
of	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
antibodies	O
at	O
diagnosis	O
,	O
showed	O
low	O
sensitivity	O
and	O
specificity	O
for	O
RR	O
prediction	O
,	O
indicating	O
low	O
applicability	O
of	O
serological	O
tests	I:C0036743
for	O
RR	O
prognosis	O
.	O

Overall	O
,	O
detection	O
of	O
anti-PGL	B:C0243095
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
antibodies	O
at	O
diagnosis	O
,	O
showed	O
low	O
sensitivity	O
and	O
specificity	O
for	O
RR	O
prediction	O
,	O
indicating	O
low	O
applicability	O
of	O
serological	O
tests	I:C0036743
for	O
RR	O
prognosis	O
.	O

Overall	O
,	O
detection	O
of	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	B:C0243095
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
antibodies	O
at	O
diagnosis	O
,	O
showed	O
low	O
sensitivity	O
and	O
specificity	O
for	O
RR	O
prediction	O
,	O
indicating	O
low	O
applicability	O
of	O
serological	O
tests	I:C0036743
for	O
RR	O
prognosis	O
.	O

Overall	O
,	O
detection	O
of	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	B:C0243095
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
antibodies	O
at	O
diagnosis	O
,	O
showed	O
low	O
sensitivity	O
and	O
specificity	O
for	O
RR	O
prediction	O
,	O
indicating	O
low	O
applicability	O
of	O
serological	O
tests	I:C0036743
for	O
RR	O
prognosis	O
.	O

Overall	O
,	O
detection	O
of	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
antibodies	B:C0003241
at	O
diagnosis	O
,	O
showed	O
low	O
sensitivity	O
and	O
specificity	O
for	O
RR	O
prediction	O
,	O
indicating	O
low	O
applicability	O
of	O
serological	O
tests	I:C0036743
for	O
RR	O
prognosis	O
.	O

Overall	O
,	O
detection	O
of	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
antibodies	O
at	O
diagnosis	B:C0011900
,	O
showed	O
low	O
sensitivity	O
and	O
specificity	O
for	O
RR	O
prediction	O
,	O
indicating	O
low	O
applicability	O
of	O
serological	O
tests	I:C0036743
for	O
RR	O
prognosis	O
.	O

Overall	O
,	O
detection	O
of	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
antibodies	O
at	O
diagnosis	O
,	O
showed	O
low	O
sensitivity	O
and	O
specificity	O
for	O
RR	B:C0343461
prediction	O
,	O
indicating	O
low	O
applicability	O
of	O
serological	O
tests	I:C0036743
for	O
RR	O
prognosis	O
.	O

Overall	O
,	O
detection	O
of	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
antibodies	O
at	O
diagnosis	O
,	O
showed	O
low	O
sensitivity	O
and	O
specificity	O
for	O
RR	O
prediction	O
,	O
indicating	O
low	O
applicability	O
of	O
serological	B:C0036743
tests	I:C0036743
for	O
RR	O
prognosis	O
.	O

Overall	O
,	O
detection	O
of	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
antibodies	O
at	O
diagnosis	O
,	O
showed	O
low	O
sensitivity	O
and	O
specificity	O
for	O
RR	O
prediction	O
,	O
indicating	O
low	O
applicability	O
of	O
serological	O
tests	I:C0036743
for	O
RR	B:C0343461
prognosis	O
.	O

Overall	O
,	O
detection	O
of	O
anti-PGL	O
-	I:C0243095
I	I:C0243095
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
and	O
anti-ND	O
-O	I:C0243095
-	I:C0243095
LID	I:C0243095
antibodies	O
at	O
diagnosis	O
,	O
showed	O
low	O
sensitivity	O
and	O
specificity	O
for	O
RR	O
prediction	O
,	O
indicating	O
low	O
applicability	O
of	O
serological	O
tests	I:C0036743
for	O
RR	O
prognosis	B:C0033325
.	O

On	O
the	O
other	O
hand	O
,	O
anti-LID	B:C0243095
-	I:C0243095
1	I:C0243095
serology	O
at	O
diagnosis	O
has	O
shown	O
prognostic	O
value	O
for	O
ENL	O
development	O
in	O
BI	O
positive	O
patients	O
.	O

On	O
the	O
other	O
hand	O
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
serology	B:C0036743
at	O
diagnosis	O
has	O
shown	O
prognostic	O
value	O
for	O
ENL	O
development	O
in	O
BI	O
positive	O
patients	O
.	O

On	O
the	O
other	O
hand	O
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
serology	O
at	O
diagnosis	B:C0011900
has	O
shown	O
prognostic	O
value	O
for	O
ENL	O
development	O
in	O
BI	O
positive	O
patients	O
.	O

On	O
the	O
other	O
hand	O
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
serology	O
at	O
diagnosis	O
has	O
shown	O
prognostic	O
value	O
for	O
ENL	B:C0343467
development	O
in	O
BI	O
positive	O
patients	O
.	O

On	O
the	O
other	O
hand	O
,	O
anti-LID	O
-	I:C0243095
1	I:C0243095
serology	O
at	O
diagnosis	O
has	O
shown	O
prognostic	O
value	O
for	O
ENL	O
development	O
in	O
BI	O
positive	B:C1446409
patients	O
.	O

ClinicalTrials.gov	B:C4086204
NCT00669643	O
.	O

